506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

计划入组 25 人 · 首次发布于 2003 年 1 月 27 日

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

计划入组 59 人 · 首次发布于 2024 年 11 月 13 日

Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

计划入组 100 人 · 首次发布于 2021 年 6 月 8 日

anti-CD20 CAR T-cell therapy

Nelarabine(Arranon, Atriance)

C₁₁H₁₅N₅O₅

Anti-CD7 CAR T-cell therapy

AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP

Australia

T-Knife GmbH

Germany

PH & T SpA

Italy

FDA Approves Larger Vial Size of Nelarabine Injection for T-Cell Leukemia and Lymphoma Treatment

FDA Accepts NDA for SH-105, a Ready-to-Dilute Formulation for Breast and Ovarian Cancer

Wugen's Allogeneic CAR-T Therapy Shows Promising Long-Term Survival Data in T-Cell Leukemia Patients